Entest Group Inc is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The Companyâ€™s current business plan is to seek new business opportunities or to engage in a business combination with an unidentified company. The Company has no operations and has not generated revenues.

Employees

Sector

Investment Holding Companies

More about the company

Market Cap	541K 473K 437K 404K 760K 51.95M 774K 5.21M 2.04M 25.44M 2.03M 1.99M 87.6M	P/E 2018	-0.92x	P/E 2019	12.6x
Enterprise Value	562K 491K 454K 420K 790K 53.99M 804K 5.42M 2.12M 26.44M 2.11M 2.06M 91.03M	EV / Sales 2018	-	EV / Sales 2019	-
Free-Float	98.54%	Yield 2018 *	-	Yield 2019	-

20-01-21	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019	CI
19-12-20	Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019	CI
19-07-15	Entest Group, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019	CI
19-01-22	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2018	CI
18-12-03	Entest Group, Inc. Announces Management Changes	CI
18-11-26	Peiwen Yu completed the acquisition of 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust.	CI
18-11-19	Peiwen Yu entered into an agreement to acquire 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust for $0.33 million.	CI
18-02-14	ENTB will Change its Name to ETNI	CI
15-11-26	Entest Group, Inc. Auditor Raises 'Going Concern' Doubt	CI
15-08-21	Entest Biomedical, Inc. will Change its Ticker to ENTB from ENTB.D	CI
15-07-27	Entest Biomedical, Inc. will Change its Ticker to ENTBD from ENTB	CI
14-07-16	Christine Ichim Joins Entest BioMedical Inc. as Director of Research	CI
13-03-06	Entest Biomedical Mulls Acquisitions	CI

20-01-21	ENTEST : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
20-01-07	ENTEST GROUP, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	AQ
19-12-20	ENTEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
18-05-10	Entest Group, Inc. : Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.	PR
17-09-13	Entest Biomedical : Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board	PR

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENTEST GROUP, INC.	-2.86%	-.--%	-	-	9.83K
EINRIDE AB	-1.44%	-25.02%	-	-	889M
CHURCHILL CAPITAL CORP XI	+14.26%	+0.57%	-	-	799M
DEEP FISSION, INC.	+1.83%	+1.78%	-	-	626M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.05%	0.00%	-	-	643M
CHURCHILL CAPITAL CORP XII	-0.47%	-1.58%	-	-	605M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.29%	-0.34%	-	-	595M
CANTOR EQUITY PARTNERS IV, INC.	0.00%	+0.43%	-	-	597M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.17%	-0.42%	-	-	584M
Average	+0.94%	-5.16%			667.09M
Weighted average by Cap.	+1.63%	-6.72%

	2018	2019
Net sales	-	-
Net income	-1.48M -1.29M -1.19M -1.1M -2.08M -142M -2.11M -14.23M -5.58M -69.49M -5.55M -5.43M -239M	192K 167K 155K 143K 269K 18.41M 274K 1.85M 724K 9.01M 720K 704K 31.03M
Net Debt	19.4K 16.95K 15.67K 14.48K 27.27K 1.86M 27.76K 187K 73.33K 912K 72.87K 71.26K 3.14M	21.2K 18.52K 17.12K 15.82K 29.79K 2.04M 30.33K 204K 80.12K 997K 79.62K 77.86K 3.43M

Entest Group, Inc. Stock Other OTC

Stocks

ETNI

US29383T3005

Investment Holding Companies

Valuation: Entest Group, Inc.

Latest news : Entest Group, Inc.

Press Releases: Entest Group, Inc.

Quotes and Performance

Managers and Directors: Entest Group, Inc.

Shell Companies

Financials

Company Profile